Richard A. Hartz

869 citations

28 papers · 464 indexed · h-index 14

Co-authors: Amos B. Smith Naoki Kanoh Haruaki Ishiyama William Roush Darin J. Gustin Jon D. Rainier Paul J. Gilligan Noriaki Minakawa
Topics: Stress Responses and Cortisol (10 papers)Alkaloids: synthesis and pharmacology (5 papers)Hormonal Regulation and Hypertension (5 papers)
Cited by: Organic Chemistry Pharmacology Behavioral Neuroscience
Journals: Journal of the American Chemical Society Journal of Medicinal Chemistry The Journal of Organic Chemistry
Partner nations: United States India Germany

In The Last Decade

Richard A. Hartz

26 papers receiving 448 citations

Peers

Countries citing papers authored by Richard A. Hartz

Since Specialization

Citations

This map shows the geographic impact of Richard A. Hartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Hartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Hartz more than expected).

Fields of papers citing papers by Richard A. Hartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Hartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Hartz. The network helps show where Richard A. Hartz may publish in the future.

Co-authorship network of co-authors of Richard A. Hartz

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Hartz. A scholar is included among the top collaborators of Richard A. Hartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Hartz. Richard A. Hartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Atropisomerism Observed in Galactose-Based Monosaccharide Inhibitors of Galectin-3 Comprising 2-Methyl-4-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione 2024 ·Journal of Medicinal Chemistry ·David Yoon,Chunjian Liu,(unknown),(unknown),Wei Wang,Jacob J. Swidorski,Li Xu,Richard A. Hartz,Satheesh K. Nair,Brett R. Beno,Manoranjan Panda,Kaushik Ghosh,(unknown),(unknown),(unknown),Arvind Mathur,Bruce A. Ellsworth,Dong Cheng,Alicia Regueiro‐Ren	3
2	Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937 2024 ·Viruses ·Brian McAuliffe,(unknown),Jie Chen,Yan Chen,Sing‐Yuen Sit,Jacob J. Swidorski,Richard A. Hartz,Li Xu,Brian L. Venables,Ny Sin,Nicholas A. Meanwell,Alicia Regueiro‐Ren,(unknown),Umesh Hanumegowda,Mark Krystal	0
3	Design, Structure–Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors 2023 ·Journal of Medicinal Chemistry ·Richard A. Hartz,Vijay T. Ahuja,Prasanna Sivaprakasam,Hong Xiao,Carol Krause,Wendy Clarke,Kevin Kish,H.A. Lewis,(unknown),R. Ramu,(unknown),(unknown),(unknown),Catherine R. Burton,John E. Macor,Gene M. Dubowchik	19
4	Synthesis, Structure–Activity Relationships, and In Vivo Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity 2022 ·Journal of Medicinal Chemistry ·Richard A. Hartz,Li Xu,Sing‐Yuen Sit,Jie Chen,Brian L. Venables,Zeyu Lin,Sharon Zhang,Zhufang Li,Dawn D. Parker,(unknown),Susan Jenkins,Umesh Hanumegowda,(unknown),Mark Krystal,Nicholas A. Meanwell,Alicia Regueiro‐Ren	2
5	Synthesis, Structure–Activity Relationships, and In Vivo Evaluation of Novel Tetrahydropyran-Based Thiodisaccharide Mimics as Galectin-3 Inhibitors 2021 ·Journal of Medicinal Chemistry ·Li Xu,Richard A. Hartz,Brett R. Beno,Kaushik Ghosh,(unknown),(unknown),Dipal Patel,(unknown),(unknown),(unknown),Anoop Kumar,Bruce A. Ellsworth,(unknown),(unknown),Dong Cheng,Alicia Regueiro‐Ren	18
6	Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF1) receptor antagonist BMS-665053 leading to improved oral bioavailability 2017 ·Bioorganic & Medicinal Chemistry Letters ·Richard A. Hartz,Vivekananda M. Vrudhula,Vijay T. Ahuja,James E. Grace,Nicholas J. Lodge,Joanne J. Bronson,John E. Macor	3
7	Potential CRF1R PET imaging agents: 1-Fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones 2013 ·Bioorganic & Medicinal Chemistry Letters ·Derek J. Denhart,Dmitry Zuev,Jonathan L. Ditta,Richard A. Hartz,Vijay T. Ahuja,Ronald J. Mattson,Hong Huang,Gail K. Mattson,(unknown),(unknown),(unknown),Nicholas J. Lodge,Joanne J. Bronson,John E. Macor	4
8	Pharmacological and behavioral characterization of the novel CRF1 antagonist BMS-763534 2012 ·Neuropharmacology ·Nicholas J. Lodge,Snježana Lelas,Yu-Wen Li,Thaddeus F. Molski,James E. Grace,Digavalli V. Sivarao,Debra J. Post-Munson,(unknown),Joanne J. Bronson,Richard A. Hartz,John E. Macor,Robert Zaczek	2
9	An Efficient, Direct Bis-ortho-chlorination of 4-(Difluoromethoxy)aniline and Its Application to the Synthesis of BMS-665053, a Potent and Selective Pyrazinone-Containing Corticotropin-Releasing Factor-1 Receptor Antagonist 2011 ·Organic Process Research & Development ·Jianqing Li,Daniel Smith,Subramaniam Krishnananthan,Richard A. Hartz,(unknown),Vijay T. Ahuja,William D. Schmitz,Joanne J. Bronson,Arvind Mathur,Joel C. Barrish,Bang‐Chi Chen	8
10	Chiral separation of potent corticotropin-releasing factor-1 receptor antagonists by supercritical fluid chromatography 2010 ·Journal of Pharmaceutical and Biomedical Analysis ·Jingfang Qian‐Cutrone,Richard A. Hartz,Vijay T. Ahuja,Vivekananda M. Vrudhula,Dauh‐Rurng Wu,R. A. Dalterio,David Wang‐Iverson,Joanne J. Bronson	4
11	Synthesis and structure–activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists 2010 ·Bioorganic & Medicinal Chemistry Letters ·Richard A. Hartz,Vijay T. Ahuja,William D. Schmitz,Thaddeus F. Molski,Gail K. Mattson,Nicholas J. Lodge,Joanne J. Bronson,John E. Macor	16
12	Development of an Efficient Synthesis of Two CRF Antagonists for the Treatment of Neurological Disorders 2010 ·Organic Process Research & Development ·David K. Leahy,Jun Li,Justin B. Sausker,Jason Zhu,(unknown),Chiajen Lai,Frédéric G. Buono,Alan Braem,Nuria de Mas,(unknown),(unknown),(unknown),Bao‐Ning Su,Qi Gao,Alicia Ng,Richard A. Hartz	11
13	Comparative Biotransformation of Pyrazinone-Containing Corticotropin-Releasing Factor Receptor-1 Antagonists: Minimizing the Reactive Metabolite Formation 2009 ·Drug Metabolism and Disposition ·Xiaoliang Zhuo,Richard A. Hartz,Joanne J. Bronson,Harvey Wong,Vijay T. Ahuja,Vivekananda M. Vrudhula,John E. Leet,Stella Huang,John E. Macor,Yue‐Zhong Shu	16
14	Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands 2005 ·Bioorganic & Medicinal Chemistry Letters ·Richard A. Hartz,Argyrios G. Arvanitis,(unknown),(unknown),(unknown),Ge Zhang,Harvey Wong,David R. Langley,Paul J. Gilligan,George L. Trainor	57
15	Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor₁ Receptor Antagonists 2004 ·Journal of Medicinal Chemistry ·Richard A. Hartz,Kausik K. Nanda,(unknown),Vijay T. Ahuja,Thaddeus F. Molski,Ge Zhang,Harvey Wong,(unknown),(unknown),Nicholas J. Lodge,Robert Zaczek,Paul J. Gilligan,George L. Trainor	9
16	Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-Releasing factor (CRF) receptor ligands 2003 ·Bioorganic & Medicinal Chemistry ·Paul J. Gilligan,(unknown),Richard A. Hartz,Stephanie C. Koch,Kausik K. Nanda,(unknown),Lawrence W. Fitzgerald,Keith J. Miller,William Marshall	21
17	Synthesis and evaluation of imidazo[1,5-a]pyrazines as corticotropin releasing hormone receptor ligands 2002 ·Bioorganic & Medicinal Chemistry Letters ·Richard A. Hartz,Paul J. Gilligan,Kausik K. Nanda,Andrew J. Tebben,(unknown),Keith J. Miller	14
18	Total Synthesis of (−)-Penitrem D 2000 ·Journal of the American Chemical Society ·Amos B. Smith,Naoki Kanoh,Haruaki Ishiyama,Richard A. Hartz	48
19	Total Synthesis of Olivomycin A J. Am. Chem. Soc. 1999, 121, 1990−1991 1999 ·Journal of the American Chemical Society ·William Roush,Richard A. Hartz,Darin J. Gustin	0
20	Tremorgenic Indole Alkaloids. 10. An Improved Asymmetric Synthesis of a Tricyclic Common Intermediate 1997 ·Israel Journal of Chemistry ·Amos B. Smith,Richard A. Hartz,P. Grant Spoors,Jon D. Rainier	12

About Richard A. Hartz

Richard A. Hartz is a scholar working on Behavioral Neuroscience, Biological Psychiatry and Pharmacology, having authored 28 papers that have together received 464 indexed citations. Recurring topics across this work include Stress Responses and Cortisol (10 papers), Alkaloids: synthesis and pharmacology (5 papers) and Hormonal Regulation and Hypertension (5 papers). The work is most often cited by research in Organic Chemistry (318 citations), Pharmacology (55 citations) and Behavioral Neuroscience (20 citations). Richard A. Hartz has collaborated with scholars based in United States, India and Germany. Frequent co-authors include Amos B. Smith, Naoki Kanoh, Haruaki Ishiyama, William Roush, Darin J. Gustin, Jon D. Rainier, Paul J. Gilligan, Noriaki Minakawa, Haifeng Cui and Vijay T. Ahuja. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact